Aaron Cravens
Bioengineer and CEO at Revel Pharmaceuticals
Co-founder and CEO at Revel Pharmaceuticals. Aaron is passionate to bring the anti-AGE therapeutics to the clinic. Previously, he worked at Google X and consulted for Bay Area biotech companies. He previously founded a startup in the skincare space and trained in Stanford’s IGNITE Business School Program. He has more than eight years of experience in Revel’s platform technologies of enzyme discovery and engineering.
He completed BS in Mathematics at the University of Rochester and received his PhD in Bioengineering from Stanford University.
Visit website: https://www.revelpharmaceuticals.com/team#AaronCravens
See also: 
Revel Pharmaceuticals
- Biotechnology company commercializing therapeutic enzymes to degrade age associated molecule damage.
Details last updated 22-Oct-2021
Aaron Cravens is also referenced in the following:
Engineered Enzymes to Break Extracellular Crosslinks - Aaron Cravens at Longevity Summit Dublin 2024
Aaron Cravens delivered a keynote on engineered enzymes to break extracellular crosslinks
Longevity Summit Dublin 2024
13-Jun-2024 to 16-Jun-2024
Event gathering Global Longevity and Rejuvenation community in Dublin by LEV Foundation (Dublin, Ireland)
Rejuvenation Startup Summit 2024
10-May-2024 to 11-May-2024
The leading networking event for rejuvenation startups, longevity investors and translational researchers by Forever Healthy Foundation
Aaron Cravens News
Reason reports back from Rejuvenation Startup Summit 2024
Fight Aging! - 13-May-2024
A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Read more...Reason reports back from October's Rejuvenation Startup Summit
Fight Aging! - 19-Oct-2022
Some really exciting developments with quite a few in clinical trials
Read more...Revel pharmaceutics raised $8.4M to push enzyme therapies to clinic
KIZOO Technology Ventures - 17-Mar-2022
Funds will be used to develop enzymes that repair collagen and reverse ageing or disease
Read more...Revel pharmaceuticals restores tissue function using AGE-cleaving enzymes
Longevity Technology - 12-Oct-2021
A unique treatment approach for ageing; will soon begin trials in animals and human cadaver tissue
Read more...
